Menu Search
Equities

Kalvista Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
4XC1:STU

Kalvista Pharmaceuticals Inc

Actions
  • Price (EUR)12.60
  • Today's Change0.40 / 3.28%
  • Shares traded0.00
  • 1 Year change+36.96%
  • Beta-0.3209
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drug therapies for diseases with significant unmet need. Its product candidate is sebetralstat, an inhibitor of plasma kallikrein being developed for hereditary angioedema (HAE). Sebetralstat is designed to offer people living with HAE a medication that can be taken as a discreet oral dose to readily treat HAE attacks on-demand, including at the earliest signs before the attack fully develops. Sebetralstat works by targeting the kallikrein-kinin system (KKS) cascade, selectively inhibiting plasma kallikrein and its uncontrolled activity that drives HAE attacks. The Company is also designing an oral Factor XIIa inhibitor for HAE prophylaxis, positioning KalVista to address the full spectrum of HAE disease management. Factor XIIa inhibitor program is developed to address other therapeutic areas, including inflammation and thrombosis.

  • Revenue in USD (TTM)15.12m
  • Net income in USD-210.31m
  • Incorporated2004
  • Employees270.00
  • Location
    Kalvista Pharmaceuticals Inc200 CROSSING BOULEVARDFRAMINGHAM 01702United StatesUSA
  • Phone+1 (857) 999-0075
  • Fax+1 (302) 531-3150
  • Websitehttps://www.kalvista.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.